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Background
Several treatment options are available for chronic rhinosi-
nusitis (CRS), but disease control remains elusive for many
patients. Recently, literature has emerged describing anti-
IgE monoclonal antibody as a potential therapy for CRS.
However, its effectiveness and safety are not well known.
The purpose of this systematic review was three-fold: to
assess the effectiveness and safety of anti-IgE monoclonal
antibody therapy for the treatment of adult patients with
CRS and to identify evidence gaps to guide future research
on anti-IgE monoclonal antibody therapy for the manage-
ment of CRS.
Methods
Methodology for the systematic review was registered
with PROSPERO (No. CRD42014007600). A comprehen-
sive literature search was performed of standard research
databases, ClinicalTrials.gov and relevant grey literature
sources. Only randomized controlled trials assessing anti-
IgE therapy in adult patients for the treatment of CRS
were included. Quality of evidence was evaluated using
the GRADE approach. Two independent reviewers
extracted data and discrepancies were settled by consen-
sus and discussion amongst the reviewers.
Results
Two studies met our inclusion criteria. The GRADE
assessment of the quality of evidence was low. Compari-
son of anti-IgE therapy to placebo, there was significant
differences in CT score and quality of life. There was a
significant improvement in Lund-McKay score (n=1, 4.0
vs. -0.5, p=0.04) and AQLQ (n=1, 0.81 vs. 0.27,
p=0.003). Mixed results were found for total nasal endo-
scopic polyp score in the two studies. No significant dif-
ference was seen with regards to nasal airflow and
olfaction as measured by PNIF and UPSIT. No serious
complications were reported with this therapy in either
trial.
Conclusions
Currently insufficient evidence exists to determine
whether anti-IgE is more effective than placebo for the
treatment of CRS. High quality studies are needed to
supplement the evidence base in order to make a firm
conclusion and to further assess anti-IgE monoclonal
antibody therapy efficacy in this population.
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